{
  "date": "2025-09-16",
  "time": "12:50:00",
  "source": "ChatGPT TradingAgents",
  "market_context": "U.S. equity markets at inflection point. Small/mid-caps outperforming. Russell 2000 up 7% in August. Fed rate cut expected Sept 16-17 FOMC. Favors catalyst-driven micro-to-mid cap trades.",
  "trades": [
    {
      "symbol": "SRRK",
      "action": "long",
      "catalyst": "FDA PDUFA Sept 22 - apitegromab approval",
      "entry": "market",
      "stop_pct": 15,
      "target": 45,
      "size_pct": 3,
      "confidence": "medium",
      "risk": "high"
    },
    {
      "symbol": "INCY",
      "action": "long",
      "catalyst": "FDA PDUFA Sept 19 - Opzelura pediatric expansion",
      "entry": "market",
      "stop_pct": 4,
      "target": 92,
      "size_pct": 5,
      "confidence": "medium-high",
      "risk": "medium"
    },
    {
      "symbol": "CBRL",
      "action": "long",
      "catalyst": "Q4 Earnings Sept 17 AMC - short squeeze setup (34% SI)",
      "entry": "market",
      "stop_pct": 8,
      "target": 60,
      "size_pct": 4,
      "confidence": "medium",
      "risk": "high"
    },
    {
      "symbol": "PASG",
      "action": "long",
      "catalyst": "Insider buying + Q4 clinical data FTD gene therapy",
      "entry": "market",
      "stop_pct": 20,
      "target": 10,
      "size_pct": 2,
      "confidence": "low-medium",
      "risk": "very high"
    },
    {
      "symbol": "RIVN",
      "action": "long",
      "catalyst": "Q3 deliveries early October - peak quarter expected",
      "entry": "market",
      "stop_pct": 12.5,
      "target": 15,
      "size_pct": 5,
      "confidence": "medium-high",
      "risk": "medium"
    }
  ],
  "risk_management": {
    "max_position_size_pct": 5,
    "stop_loss_mandatory": true,
    "portfolio_hedge": "SPY/IWM puts"
  }
}